On July 22, 2025, CVS Health (CVS, Financial) faced a price target reduction from UBS analyst Kevin Caliendo. The analyst maintained a 'Neutral' rating on the stock.
UBS revised its price target for CVS Health (CVS, Financial) to $67.00 USD, down from the previous target of $71.00 USD. This adjustment represents a percentage change of -5.63% in the price target.
Caliendo's rating remains consistent as 'Neutral,' continuing his prior outlook on the company's stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $78.68 with a high estimate of $95.00 and a low estimate of $70.00. The average target implies an upside of 27.05% from the current price of $61.93. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $85.47, suggesting a upside of 38.02% from the current price of $61.925. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
